TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
NAGE

Niagen Bioscience, Inc.

Healthcare · Biotechnology · —

3.30$ +1.9% vs. previous close Closing price · As of: Aug 25, 2026

Statements

Segments

US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Niagen Bioscience, Inc. (NAGE). It shows which part of the business is growing — and which one is holding it back.

Revenue by business segment

Revenue by business segment — NAGE
Segment 2021 2022 2023 2024 2025
Consumer Products segment $56.7M 84.1% $60.1M 83.4% · +6.0% $69.5M 83.2% · +15.7% $76.8M 77.1% · +10.4% $97.7M 75.5% · +27.2%
Ingredients segment $7.4M 11.0% $8.7M 12.1% · +17.9% $11.1M 13.3% · +27.5% $19.8M 19.9% · +77.9% $28.7M 22.2% · +44.7%
Analytical Reference Standards and Services segment $3.3M 4.9% $3.2M 4.4% · -4.0% $2.9M 3.5% · -9.3% $3.0M 3.0% · +3.6% $3.1M 2.4% · +2.2%
Pharmaceuticals segment $0 0.0% $0 0.0%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Operating income — NAGE
Segment 2021 2022 2023 2024 2025
Consumer Products segment $5.6M 9.9% $6.5M 10.8% $14.5M 20.8% $17.2M 22.4% $28.4M 29.1%
Ingredients segment $3.7M 50.3% $3.6M 41.3% $5.4M 48.7% $10.9M 55.0% $16.7M 58.4%
Analytical Reference Standards and Services segment -$10.0K -0.3% -$459.0K -14.3% -$522.0K -18.0% -$215.0K -7.1% $396.0K 12.9%
Pharmaceuticals segment -$1.8M -$2.2M

Large figure: segment operating income. Below it the margin, that is operating income measured against the revenue of the same segment.

Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.

Data as of: August 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?